TrialBMC cancer2016

Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.

Ralph Boccia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.